Login to Your Account



Alkermes beats Street but shares nicked as pain drug halted

By Marie Powers
Staff Writer

Tuesday, February 24, 2015
Despite fourth quarter and full-year financial results that topped analyst expectations, Alkermes plc saw shares (NASDAQ:ALKS) slide Tuesday after the company halted development of pain candidate ALKS 7106 following disappointing phase I results.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription